Berlin Heals Reports Positive First-in-Human Results for Less Invasive Heart Failure Device in CMIC-III Study

Key Takeaways

• Berlin Heals’ first-in-class heart failure device showed significant improvements in left ventricular ejection fraction, walking capacity, and quality of life in first-in-human study
• The less invasive approach represents a potential breakthrough for heart failure patients who currently have limited treatment options
• Results were presented at Heart Rhythm Society’s Congress, marking the first public disclosure of this novel therapeutic approach

---

CHICAGO - Berlin Heals Holding AG reported positive results from its CMIC-III first-in-human study of a novel less invasive heart failure device, marking a significant milestone for the clinical-stage medical device company. The data, presented during a high-impact session at the Heart Rhythm Society’s Congress in Chicago on April 24, 2026, demonstrated meaningful improvements across multiple cardiac endpoints.

Study Results Show Multi-Parameter Improvements

The CMIC-III study evaluated Berlin Heals’ first-in-class device in heart failure patients, measuring key clinical outcomes including left ventricular ejection fraction (LVEF), functional capacity, and quality of life measures. Results showed statistically significant improvements in:

• Left Ventricular Ejection Fraction (LVEF): A critical measure of heart pumping efficiency
• 6-Minute Walk Test (6MWT): Indicating improved functional capacity and exercise tolerance
• Quality of Life (QOL) scores: Reflecting patient-reported outcomes
• New York Heart Association (NYHA) class: The standard classification system for heart failure severity

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for heart failure. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Addressing Critical Unmet Need in Heart Failure

Heart failure affects over 6 million Americans and represents a $30+ billion annual healthcare burden. Current treatment options are limited, particularly for patients who are not candidates for more invasive surgical interventions. Berlin Heals’ less invasive approach could potentially expand treatment options for a broader patient population.

The company’s device represents a novel mechanism of action in the heart failure space, differentiating it from existing therapies offered by established players like Medtronic, Abbott, and Boston Scientific. The less invasive nature of the procedure could reduce patient risk while maintaining therapeutic efficacy.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Clinical Development and Market Implications

As a first-in-human study, CMIC-III represents the earliest stage of clinical validation for Berlin Heals’ technology. While the positive results are encouraging, the company will need to advance through larger, controlled trials to establish commercial viability and regulatory approval.

The heart failure device market is highly competitive, with established companies holding significant market share. However, Berlin Heals’ first-in-class positioning and less invasive approach could provide competitive advantages if validated in larger studies.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for heart failure pricing, access, and launch sequencing.

Next Steps and Timeline

Following these positive Phase I results, Berlin Heals is expected to initiate larger clinical trials to further validate the device’s safety and efficacy. The company has not yet disclosed specific timelines for next-phase studies or regulatory submissions.

The presentation at Heart Rhythm Society’s Congress represents the first public disclosure of results from this novel therapeutic approach, potentially attracting attention from investors, partners, and regulatory agencies interested in innovative heart failure treatments.

IntelligenceStrategic Takeaways▾

Berlin Heals’ first-in-class heart failure device showed significant improvements in left ventricular ejection fraction, walking capacity, and quality of life in first-in-human study The less invasive approach represents a potential breakthrough for heart failure patients who currently have limited treatment options Results were presented at Heart Rhythm Society’s Congress, marking the first public disclosure of this novel therapeutic approach

Investment and Partnership Implications

The positive first-in-human results could strengthen Berlin Heals’ position for future funding rounds and potential strategic partnerships. Medical device companies often seek innovative technologies that can differentiate their portfolios in competitive therapeutic areas like cardiovascular disease.

However, investors should note the early-stage nature of the data and the significant development pathway ahead before potential commercialization.

---

Frequently Asked Questions

What does this mean for heart failure patients?

The positive results suggest Berlin Heals’ device could offer a new, less invasive treatment option for heart failure patients. However, this is very early-stage data, and the device would need to complete additional clinical trials and receive regulatory approval before becoming available to patients.

When will Berlin Heals’ heart failure device be available?

The device is still in early clinical development following first-in-human testing. Berlin Heals has not disclosed timelines for larger trials or regulatory submissions, but medical devices typically require several years of additional testing before potential market approval.

How does this compare to existing heart failure treatments?

Berlin Heals’ device is described as first-in-class with a less invasive approach compared to current surgical options. While early results are promising across multiple cardiac measures, direct comparisons to existing treatments would require head-to-head clinical studies.

Related coverage

• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• J&J reports positive Phase 3 Tremfya data in ulcerative colitis
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial